CDER Loses Its Chief: When the Drug Center's Top Reviewer Walks Mid-Cycle

Three Exits, Fifteen Days

In mid-May 2026, three of the FDA's most senior interpretive seats turned over inside fifteen days. Commissioner Marty Makary resigned on May 12. On May 15, Endpoints News reported that Tracy Beth Høeg, head of the Center for Drug Evaluation and Research, was expected to depart. This followed Vinay Prasad's exit from CBER — the FDA's biologics and vaccines center — at the end of April.

The day-to-day review machinery does not stop in moments like this. Filing reviews continue. Information Requests continue. PDUFA clocks keep running. What changes is the interpretive layer above the review — and submissions that depended on it.

The Office of New Drugs sits inside CDER. So does the biosimilars division. So does the entire CDER guidance pipeline. The person at the top of that org sets the lens through which every NDA, BLA, and 351(k) submission is read. Losing that person mid-cycle is not a routine event for a sponsor whose drug is mid-review.

What CDER Leadership Actually Touches

Three things sit on the CDER chief's desk that matter to a sponsor with an active submission.

Cross-division interpretive consistency. When a Type B meeting hands a sponsor a position that conflicts with what the safety reviewer said two months earlier, the resolution chain runs up through CDER leadership. Interim leadership defers more, escalates more carefully, and waits for clearer authority on novel questions. The cost is timeline drift on every program where the writer needs a definitive interpretation to anchor the narrative.

Pilot programs and accelerated pathways. CDER runs the bulk of the FDA's discretionary mechanisms — breakthrough therapy designation, accelerated approval consultations, Project Optimus dose optimization conversations. Anything that requires the center's explicit endorsement of a non-standard approach gets a more cautious read during transitions.

Guidance finalization. CDER's guidance pipeline includes documents that have been in draft for years. Draft guidance does not get finalized during transitions. Final guidance under revision often stays under revision. The corpus that exists today is the corpus your writer should be drafting against for the next two quarters, minimum.

The career reviewers reading your CSR are still reading it. The signal-vs-noise filter is at the top, not in the middle — which is exactly why writing that anticipates the top of the chain, rather than depending on it, holds up.

Reviewer-Agnostic Writing

The discipline that gets exposed in periods like this is whether a sponsor's writing was built to depend on a specific reviewer relationship — or built to stand on its own.

Submissions that were written to anticipate the questions, cite the relevant guidance explicitly, lay out alternative analyses in the appendix, and resolve foreseeable interpretive ambiguities in the text — those submissions do disproportionate work in transitional periods. The reviewer who picks them up does not need to escalate. The reviewer's manager does not need to call up the chain for a definitive read.

Submissions that were written assuming the sponsor's existing relationship with a specific division would carry the ambiguous calls — those submissions slow down in transitional periods. Every ambiguous call is now a longer round trip than it was a month ago.

This is not a new principle. It is the principle that every senior regulatory writer was taught and that gets forgotten the longer a program runs with a stable review team. The current FDA leadership turnover is making it visible again.

The 60-Day Reset

Sponsors with submissions in active CDER review should do four concrete things over the next 60 days.

Re-read the briefing document. Read it as a reviewer who has never spoken to your team. Mark every spot where the text assumes a prior conversation, a prior decision, or a prior relationship. Those are the spots where an interim reviewer is going to send an Information Request. Either rewrite the section to stand on its own, or pre-empt the IR with a short appendix.

Inventory the in-flight Information Requests. For each IR awaiting response, check whether the response leans on a verbal alignment that was reached in a meeting two quarters ago. If yes, restate the alignment explicitly in the response and reference the meeting minutes. Do not assume institutional memory across a leadership transition.

Plan the next Type B / Type C meeting for the existing guidance corpus. Build the briefing document against published guidance, not against the draft guidance you were hoping would land first. If the draft drops mid-cycle, you can add a supplement. If it does not, your meeting is still on solid ground.

Identify the two informational triggers that will sharpen the picture. Those are: the next named CDER acting director, and the next named Commissioner. Plan for both names to land inside a 60–90 day window. Plan the submission cadence so the next major milestone is not gated on either name.

What Holds

Existing CDER guidance is the operative reference. Existing meeting decisions hold. Existing review timelines hold. The PDUFA clocks keep running. The reviewers reading your file keep reading it.

The discipline this requires is to treat the existing published guidance and existing meeting record as the foundation of submission strategy — not as a transient state about to be replaced. Teams that build their narratives against "the new direction we expect when the next chief is named" will rewrite those narratives twice. Teams that build their narratives against what exists, and add supplements when new direction lands, will run cleaner cycles.

The larger lesson from the past fifteen days is not that the FDA is unstable. The FDA has run through commissioner transitions before. The lesson is that the writing function is what carries continuity when the review function is in flux. A submission that reads cleanly to any qualified reviewer — not the specific reviewer the sponsor had been building rapport with — is the only kind of submission that survives a turnover year intact.

The work itself does not change. The way the work is written has to.